TrialJournal for immunotherapy of cancer2026

Phase II study of olaparib and durvalumab in patients with metastatic castration-resistant prostate cancer.

Chennan Li et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.